Griet Compernolle

2.4k total citations · 1 hit paper
50 papers, 1.8k citations indexed

About

Griet Compernolle is a scholar working on Genetics, Immunology and Epidemiology. According to data from OpenAlex, Griet Compernolle has authored 50 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Genetics, 19 papers in Immunology and 18 papers in Epidemiology. Recurrent topics in Griet Compernolle's work include Inflammatory Bowel Disease (27 papers), Microscopic Colitis (16 papers) and Immunodeficiency and Autoimmune Disorders (13 papers). Griet Compernolle is often cited by papers focused on Inflammatory Bowel Disease (27 papers), Microscopic Colitis (16 papers) and Immunodeficiency and Autoimmune Disorders (13 papers). Griet Compernolle collaborates with scholars based in Belgium, Slovenia and Netherlands. Griet Compernolle's co-authors include Ann Gils, Séverine Vermeire, Gert Van Assche, Marc Ferrante, Niels Vande Casteele, Vera Ballet, Paul Rutgeerts, Kristel Van Steen, Steven Simoens and Paul Declerck and has published in prestigious journals such as Journal of Biological Chemistry, Gastroenterology and Journal of Molecular Biology.

In The Last Decade

Griet Compernolle

50 papers receiving 1.8k citations

Hit Papers

Trough Concentrations of Infliximab Guide Dosing for Pati... 2015 2026 2018 2022 2015 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
    2015 636 citations Niels Vande Casteele, Marc Ferrante et al. Gastroenterology profile →

Peers

Griet Compernolle
Scott Hauenstein United States
Luigi D. Notarangelo Italy
J Gordon United Kingdom
Jan M. H. van den Brande Netherlands
Elena Pérez United States
Pradip N. Akolkar United States
Lisa M. Shackelton United States
Michel Barrois France
Michael Cullen United States
Christoph Springfeld Germany
Scott Hauenstein United States
Griet Compernolle
Citations per year, relative to Griet Compernolle Griet Compernolle (= 1×) peers Scott Hauenstein

Countries citing papers authored by Griet Compernolle

Since Specialization
Citations

This map shows the geographic impact of Griet Compernolle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Griet Compernolle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Griet Compernolle more than expected).

Fields of papers citing papers by Griet Compernolle

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Griet Compernolle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Griet Compernolle. The network helps show where Griet Compernolle may publish in the future.

Co-authorship network of co-authors of Griet Compernolle

This figure shows the co-authorship network connecting the top 25 collaborators of Griet Compernolle. A scholar is included among the top collaborators of Griet Compernolle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Griet Compernolle. Griet Compernolle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Peeters, Miet, et al.. (2020). Development and validation of immunoassays for monitoring of guselkumab and anti-guselkumab antibodies in patients with moderate-to-severe psoriasis. Journal of Pharmaceutical and Biomedical Analysis. 189. 113433–113433. 4 indexed citations
2.
Verstockt, Bram, Erwin Dreesen, Maja Noman, et al.. (2019). Ustekinumab Exposure-outcome Analysis in Crohn’s Disease Only in Part Explains Limited Endoscopic Remission Rates. Journal of Crohn s and Colitis. 13(7). 864–872. 80 indexed citations
3.
Hanžel, Jurij, Ivan Ferkolj, Borut Štabuc, et al.. (2019). Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease. United European Gastroenterology Journal. 7(6). 741–749. 21 indexed citations
4.
Bian, Sumin, Thomas Van Stappen, Filip Baert, et al.. (2016). Generation and characterization of a unique panel of anti-adalimumab specific antibodies and their application in therapeutic drug monitoring assays. Journal of Pharmaceutical and Biomedical Analysis. 125. 62–67. 28 indexed citations
5.
Casteele, Niels Vande, Marc Ferrante, Gert Van Assche, et al.. (2015). Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease. Gastroenterology. 148(7). 1320–1329.e3. 636 indexed citations breakdown →
6.
Gils, Ann, Niels Vande Casteele, Marlies Van de Wouwer, et al.. (2014). Development of a Universal Anti-Adalimumab Antibody Standard for Interlaboratory Harmonization. Therapeutic Drug Monitoring. 36(5). 669–673. 39 indexed citations
7.
Casteele, Niels Vande, Marc Peeters, Marc Ferrante, et al.. (2014). P484 Functional cellular based assay reveals neutralising anti-drug antibodies in IBD patients treated with maintenance adalimumab. Journal of Crohn s and Colitis. 8. S268–S269. 1 indexed citations
8.
Drobne, David, Peter Bossuyt, Christine Breynaert, et al.. (2014). Withdrawal of Immunomodulators After Co-treatment Does Not Reduce Trough Level of Infliximab in Patients With Crohn’s Disease. Clinical Gastroenterology and Hepatology. 13(3). 514–521.e4. 100 indexed citations
9.
Casteele, Niels Vande, Ann Gils, Vera Ballet, et al.. (2013). Randomised Controlled Trial of Drug Level Versus Clinically Based Dosing of Infliximab Maintenance Therapy in IBD: Final Results of the TAXIT Study. United European Gastroenterology Journal. 1. 27 indexed citations
10.
Casteele, Niels Vande, Griet Compernolle, Vera Ballet, et al.. (2012). OP11 Individualised infliximab treatment using therapeutic drug monitoring: A prospective controlled Trough level Adapted infliXImab Treatment (TAXIT) trial. Journal of Crohn s and Colitis. 6. S6–S6. 32 indexed citations
11.
Mishra, Niraj, et al.. (2012). Increased zymogen activity of thrombin‐activatable fibrinolysis inhibitor prolongs clot lysis. Journal of Thrombosis and Haemostasis. 10(6). 1091–1099. 8 indexed citations
12.
Drobne, David, Peter Bossuyt, Christine Breynaert, et al.. (2011). Long term evolution and impact of immunomodulator cotreatment and withdrawal on infliximab on trough levels in 223 patients with Crohn's disease. Open Repository and Bibliography (University of Liège). 2 indexed citations
13.
Compernolle, Griet, et al.. (2011). TAFIa inhibiting nanobodies as profibrinolytic tools and discovery of a new TAFIa conformation. Journal of Thrombosis and Haemostasis. 9(11). 2268–2277. 23 indexed citations
14.
Dewilde, Maarten, Griet Compernolle, Jeppe Buur Madsen, et al.. (2010). Subtle structural differences between human and mouse PAI-1 reveal the basis for biochemical differences. Journal of Structural Biology. 171(1). 95–101. 16 indexed citations
15.
Herreweghe, Joris M. Van, Lise Vanderkelen, L. Callewaert, et al.. (2010). Lysozyme inhibitor conferring bacterial tolerance to invertebrate type lysozyme. Cellular and Molecular Life Sciences. 67(7). 1177–1188. 36 indexed citations
16.
Vancraenenbroeck, Renée, et al.. (2008). Discovery of novel mechanisms and molecular targets for the inhibition of activated thrombin activatable fibrinolysis inhibitor. Journal of Thrombosis and Haemostasis. 6(11). 1892–1899. 20 indexed citations
17.
18.
Taeye, Bart De, Griet Compernolle, & Paul Declerck. (2004). Site-directed Targeting of Plasminogen Activator Inhibitor-1 as an Example for a Novel Approach in Rational Drug Design. Journal of Biological Chemistry. 279(19). 20447–20450. 3 indexed citations
19.
Gils, Ann, et al.. (2003). Elucidation of a novel epitope of a substrate-inducing monoclonal antibody against the serpin PAI-1. Journal of Thrombosis and Haemostasis. 1(5). 1028–1033. 13 indexed citations
20.
Taeye, Bart De, et al.. (2003). Immobilization of the Distal Hinge in the Labile Serpin Plasminogen Activator Inhibitor 1. Journal of Biological Chemistry. 278(26). 23899–23905. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Scott Hauenstein Breakdown of academic impact, for papers by Luigi D. Notarangelo Breakdown of academic impact, for papers by J Gordon Breakdown of academic impact, for papers by Jan M. H. van den Brande Breakdown of academic impact, for papers by Elena Pérez Breakdown of academic impact, for papers by Pradip N. Akolkar Breakdown of academic impact, for papers by Lisa M. Shackelton Breakdown of academic impact, for papers by Michel Barrois Breakdown of academic impact, for papers by Michael Cullen Breakdown of academic impact, for papers by Christoph Springfeld
Rankless by CCL
2026